GVB Biofarma, a global manufacturer of canbinoids, has opened a separation facility.
This feature, developed in almost two years of planning and engineering, allows GVB Biofarma to meet the developed demands of global hemp and canbinoid markets.
“Our new separation feature represents a major milestone for GVB bioforma,” said GVB Biofarma CEO Drew Speigel. “We have designed this operation to ensure ultra-high throwput capacity while maintaining strict neutraxutical CGMP compliance. As a result, we increase production production significantly and our ever-expansion, sophisticated customer base required rigorous standards Are deployed to complete. “
This facility has the ability to produce more than 300,000 kg of isolates per year. This capacity replaces GVB biofarma to obtain up to $ 100 million in the annual recurring revenue (ARR) while maintaining product integrity and stability. With large batch size and proprietary separation and purification processes, the convenience provides high-deficit yields.
“From the very first day, our focus has been on setting a new industry standard in both scale and precision,” said GVB Biofarma COO Phil Swindelles. “This state-of-the-art feature underlines our commitment to distribute top-quality, high-virtue of canbinoid isolates. We are excited to meet our customers’ developed needs with this unprecedented level of production and stability.”
